 |
 |
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
The Metabolic Syndrome and Fatty Liver Disease
15 November 2005 | Volume 143 Issue 10 | Page I-70
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease." It is in the 15 November 2005 issue of Annals of Internal Medicine (volume 143, pages 722-728). The authors are M. Hamaguchi, T. Kojima, N. Takeda, T. Nakagawa, H. Taniguchi, K. Fujii, T. Omatsu, T. Nakajima, H. Sarui, M. Shimazaki, T. Kato, J. Okuda, and K. Ida.
What is the problem and what is known about it so far?
The metabolic syndrome is a condition in which people have at least 3 of the following abnormalities: overweight, high blood pressure, high triglyceride levels (a bad type of fat in the blood), low high-density lipoprotein cholesterol levels ("good" cholesterol), and high blood sugar levels. People with the metabolic syndrome are at risk for type 2 diabetes and cardiovascular disease, including heart attack and stroke. Nonalcoholic fatty liver disease is a condition where fat deposits in the liver. Alcohol use also leads to fatty deposits in the liver, which is why nonalcoholic fatty liver disease specifically refers to fatty liver in people who do not consume alcohol. Nonalcoholic fatty liver disease is generally not a serious condition and rarely leads to more serious liver problems, but it can interfere with normal liver function. Previous studies have shown associations of some of the individual features of metabolic syndrome with nonalcoholic fatty liver disease; however, they have not looked at what happens to the liver over time in people with the metabolic syndrome.
Why did the researchers do this particular study?
To examine the association of the metabolic syndrome with nonalcoholic fatty liver disease over time.
Who was studied?
4401 healthy Japanese adults who were participating in a medical checkup program at a general hospital in Japan.
How was the study done?
As part of the checkup program, the participants completed yearly questionnaires about their health, had blood tests for liver and metabolic function, and had ultrasonographic examinations of their abdomens. Ultrasonography can identify fatty deposits in the liver.
What did the researchers find?
Of the 4401 patients in the study, 812 (18%) had nonalcoholic fatty liver disease at the start of the study. This disease was more common in persons with the metabolic syndrome than in persons who did not have the metabolic syndrome. Over the course of the study, 308 participants developed nonalcoholic fatty liver disease. In addition, 113 participants who had the disease at the start of the study did not have it at the end of the study. Participants who had the metabolic syndrome were more likely than those who did not have it to develop nonalcoholic fatty liver disease over time. Nonalcoholic fatty liver disease was less likely to resolve over the course of the study if the participants had the metabolic syndrome than if they did not.
What were the limitations of the study?
The study included only Japanese participants and may not apply to people with other ethnic backgrounds. Ultrasonography is not the best way to identify nonalcoholic fatty liver disease.
What are the implications of the study?
Nonalcoholic fatty liver disease is another health problem associated with the metabolic syndrome. This study suggests that reversing the metabolic syndrome may reverse the disease. However, additional studies are needed to prove that this is true.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel The Metabolic Syndrome Endocr. Rev., December 1, 2008; 29(7): 777 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marchesini, S. Moscatiello, S. Di Domizio, and G. Forlani Obesity-Associated Liver Disease J. Clin. Endocrinol. Metab., November 1, 2008; 93(11_Supplement_1): s74 - s80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Kumanyika, E. Obarzanek, N. Stettler, R. Bell, A. E. Field, S. P. Fortmann, B. A. Franklin, M. W. Gillman, C. E. Lewis, W. C. Poston II, et al. Population-Based Prevention of Obesity: The Need for Comprehensive Promotion of Healthful Eating, Physical Activity, and Energy Balance: A Scientific Statement From American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (Formerly the Expert Panel on Population and Prevention Science) Circulation, July 22, 2008; 118(4): 428 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kotronen and H. Yki-Jarvinen Fatty Liver: A Novel Component of the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 27 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Musso, R. Gambino, F. De Michieli, G. Biroli, A. Premoli, G. Pagano, S. Bo, M. Durazzo, and M. Cassader Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake Am. J. Clinical Nutrition, September 1, 2007; 86(3): 661 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilainen, and H. Yki-Jarvinen Liver Fat in the Metabolic Syndrome J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3490 - 3497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Grattagliano, P. Portincasa, V. O. Palmieri, and G. Palasciano Managing nonalcoholic fatty liver disease: Recommendations for family physicians Can Fam Physician, May 1, 2007; 53(5): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chang, S. Ryu, E. Sung, and Y. Jang Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease Clin. Chem., April 1, 2007; 53(4): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. N. Nicolaou, J. E. Papadakis, E. N. Karatzis, S. I. Dermitzaki, A. K. Tsakiris, and P. D. Skoufas Impact of the Metabolic Syndrome on Atrial Size in Patients With New-Onset Atrial Fibrillation Angiology, February 1, 2007; 58(1): 21 - 25. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Grundy Gamma-Glutamyl Transferase: Another Biomarker for Metabolic Syndrome and Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 4 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maggio, F. Lauretani, G. P. Ceda, S. Bandinelli, S. Basaria, G. Paolisso, A. Ble, J. M. Egan, E. J. Metter, A. M. Abbatecola, et al. Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E353 - E358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. V. Gentilucci, D. Santini, B. Vincenzi, E. Fiori, A. Picardi, and G. Tonini Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients J. Clin. Oncol., December 1, 2006; 24(34): 5467 - 5467. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.D.H. Malnick and H. Knobler The medical complications of obesity QJM, September 1, 2006; 99(9): 565 - 579. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ishizaka, Y. Ishizaka, H. Hashimoto, E.-I. Toda, R. Nagai, and M. Yamakado Metabolic Syndrome May Not Associate With Carotid Plaque in Subjects With Optimal, Normal, or High-Normal Blood Pressure Hypertension, September 1, 2006; 48(3): 411 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, S. Jalkanen, K. E. J. Airaksinen, J. Knuuti, R. Parkkola, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E282 - E290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-N. Vauthey, T. M. Pawlik, D. Ribero, T.-T. Wu, D. Zorzi, P. M. Hoff, H. Q. Xiong, C. Eng, G. Y. Lauwers, M. Mino-Kenudson, et al. Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases J. Clin. Oncol., May 1, 2006; 24(13): 2065 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Reddy and M. Sambasiva Rao Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation Am J Physiol Gastrointest Liver Physiol, May 1, 2006; 290(5): G852 - G858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Chavez-Tapia, N. Mendez-Sanchez, and M. Uribe The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med, March 7, 2006; 144(5): 379 - 379. [Full Text] [PDF]
|
|
|
|
|
|
Y. Kida and T. Sato The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med, March 7, 2006; 144(5): 379 - 380. [Full Text] [PDF]
|
|
|
|
 |
|
 JournalScan Gut, March 1, 2006; 55(3): 425 - 425. [Full Text] [PDF]
|
|
|
|
 |
|
 Metabolic Syndrome Predicts NAFLD Journal Watch Gastroenterology, February 14, 2006; 2006(214): 8 - 8. [Full Text]
|
|
|
|
|
|
E. E. Powell, J. R. Jonsson, and A. D. Clouston Dangerous Liaisons: The Metabolic Syndrome and Nonalcoholic Fatty Liver Disease Ann Intern Med, November 15, 2005; 143(10): 753 - 754. [Full Text] [PDF]
|
|
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
